Document is current
Any future updates will be listed below
-
Authors
Debinski, Waldemar
Fink, Kaitlin N.
Rossmeisl, John
Mott, Ryan T.
Watabe, Kounosuke
D’Agostino, Ralph
Thomas, Alexandra
Herpai, Denise
-
Funding
Funding for this research was provided by:
USA National Cancer Institute (R01CA256285)
Dallas Swing Fund and Broyhill Family Fund (To Brain Tumor Center of Excellence)
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 5 August 2025
First Online: 27 October 2025
Declarations
:
: Not applicable.
: No part of the manuscript is under consideration, in press, published, or reported in a scientific journal in the form of manuscript. All authors read and approved the manuscript. All authors consent to publication.
: Waldemar Debinski is a co-inventor on several patent applications related to the subject of this manuscript; several of them have been licensed to WPD Pharmaceuticals. Kaitlin N. Fink, Ryan T. Mott, and Kounosuke Watabe have nothing to disclose. John Rossmeisl is a co-inventor on a patent application covering QUAD-DM1 cytotoxin. Alexandra Thomas reports stock ownership: Johnson & Johnson, Gilead Sciences, Bristol Myers Squibb, Pfizer; consulting or advisory role: Genentech, AstraZeneca; Research Funding: Sanofi, Merck (to the institution); royalties. Denise Herpai is a co-inventor on several patent applications related to the subject of this manuscript; several of them have been licensed to WPD Pharmaceuticals.
